Immutep Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Canc
 

Immutep S.A. announced the final results from its Phase I/II chemoimmunotherapy clinical trial in metastatic breast carcinoma. The final results confirm the clinical response rate of 50 percent using Immutep's IMP321 associated with paclitaxel. This compares to 25 percent using paclitaxel alone. ImmuFact(R) IMP321 is a T cell immunostimulatory agent...

More...